Oral Presentations

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine Chen, Princess Margaret Cancer Centre
141
653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Saturday, December 7, 2019; 9:30-11:00 AM ET
Orange County Convention Center, Hall E1

Posters:

Company-Sponsored Studies

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Ajai Chari, Icahn School of Medicine at Mount Sinai
1854
653. Myeloma: Therapy, excluding Transplantation: Poster I
Saturday, December 7, 2019; 5:30-7:30 PM ET
Orange County Convention Center, Hall B

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

Ajay Nooka, Winship Cancer Institute, Emory University School of Medicine
1872
653. Myeloma: Therapy, excluding Transplantation: Poster I
Saturday, December 7, 2019; 5:30-7:30 PM ET
Orange County Convention Center, Hall B

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Darrell White, Dalhousie University
3165
653. Myeloma: Therapy, excluding Transplantation: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)

Cristina Gasparetto, Duke University Medical Center
3157
653. Myeloma: Therapy, excluding Transplantation: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Andrew Yee, Massachusetts General Hospital
3140
653. Myeloma: Therapy, excluding Transplantation: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

A Machine Learning Approach Identifies a 30-gene Model that Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, Icahn School of Medicine at Mount Sinai
3101
652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, Weill Cornell School of Medicine
2997
637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Luciano Costa, University of Alabama at Birmingham
3125
653. Myeloma: Therapy, excluding Transplantation: Poster II
Date: Sunday, December 8, 2019; 6:00 PM – 8:00 PM ET
Orange County Convention Center, Hall B

Investigator-Sponsored Studies

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy Pardee, Comprehensive Cancer Center, Wake Forest Baptist Health
1388
616. Acute Myeloid Leukemia: Novel Therapy, excluding
Saturday, December 7, 2019; 5:30-7:30 PM ET
Orange County Convention Center, Hall B

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, Moffitt Cancer Center
3314
731. Clinical Autologous Transplantation: Results: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc

Yuki Nishida, The University of Texas MD Anderson Cancer Center
2556
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
Sunday, December 8, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah Stephens, Huntsman Cancer Institute, University of Uta
4310
642. CLL: Therapy, excluding Transplantation: Poster III
Monday, December 9, 2019; 6:00-8:00 PM ET
Orange County Convention Center, Hall B

Link to Abstracts